SERPINB2

Summary

Gene Symbol: SERPINB2
Description: serpin family B member 2
Alias: HsT1201, PAI, PAI-2, PAI2, PLANH2, plasminogen activator inhibitor 2, monocyte Arg-serpin, placental plasminogen activator inhibitor, plasminogen activator inhibitor, type II (arginine-serpin), serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2, serpin B2, serpin peptidase inhibitor, clade B (ovalbumin), member 2, urokinase inhibitor
Species: human

Top Publications

  1. doi Gingival crevicular fluid IL-6, tPA, PAI-2, albumin levels following initial periodontal treatment in chronic periodontitis patients with or without type 2 diabetes
    Levent Kardesler
    Department of Periodontology, School of Dentistry, Ege University, 35100 Bornova, Izmir, Turkey
    Inflamm Res 60:143-51. 2011
  2. ncbi Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3
    A J Bartuski
    Joint Program in Neonatology, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genomics 43:321-8. 1997
  3. ncbi Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin
    Andrea Varro
    Physiological Laboratory, University of Liverpool, Liverpool, England
    Gastroenterology 123:271-80. 2002
  4. doi Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2
    Lee Major
    Queensland Institute of Medical Research, Brisbane, PO Royal Brisbane Hospital, Queensland 4029, Australia
    Exp Cell Res 317:338-47. 2011
  5. pmc Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1
    Simon Almeida-Vega
    Physiological Laboratory, School of Biomedical Sciences, University of Liverpool, Liverpool, UK
    Am J Physiol Gastrointest Liver Physiol 296:G414-23. 2009
  6. doi Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, Australia
    Thromb Haemost 104:1133-42. 2010
  7. pmc Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli
    Joanna Boncela
    Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland
    J Biol Chem 286:43164-71. 2011
  8. ncbi SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication
    Grant A Darnell
    Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    J Biol Chem 281:31348-58. 2006
  9. ncbi Lewis phenotypes and the insulin resistance syndrome in young healthy white men and women
    J O Clausen
    Medical Department C, Glostrup Hospital, Copenhagen, Denmark
    Am J Hypertens 8:1060-6. 1995
  10. ncbi Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension
    J R Jeng
    Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    Am J Hypertens 11:235-9. 1998

Research Grants

  1. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
  2. William P Fay; Fiscal Year: 2016
  3. RICHARD LOUIS KLEIN; Fiscal Year: 2015
  4. Urokinase, Neutrophil Activation and Acute Lung Injury.
    Gang Liu; Fiscal Year: 2013
  5. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
  6. DOUGLAS EUGENE VAUGHAN; Fiscal Year: 2016
  7. Zhongwu Liu; Fiscal Year: 2014
  8. REGULATION OF VASCULAR FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 2003
  9. MOLECULAR INTERACTIONS OF FIBRINOLYSIS
    John Anagli; Fiscal Year: 2005
  10. Regulation of Pal-1 in Atherosclerosis and Thrombosis
    Yolanda M Fortenberry; Fiscal Year: 2013

Patents

  1. VARIANTS OF PAI-2
  2. POLYPEPTIDE PRODUCTION IN FUNGI

Detail Information

Publications360 found, 100 shown here

  1. doi Gingival crevicular fluid IL-6, tPA, PAI-2, albumin levels following initial periodontal treatment in chronic periodontitis patients with or without type 2 diabetes
    Levent Kardesler
    Department of Periodontology, School of Dentistry, Ege University, 35100 Bornova, Izmir, Turkey
    Inflamm Res 60:143-51. 2011
    To evaluate initial periodontal treatment effects on gingival crevicular fluid (GCF) interleukin-6 (IL-6), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-2 (PAI-2), albumin levels in type 2 diabetic patients.
  2. ncbi Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3
    A J Bartuski
    Joint Program in Neonatology, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genomics 43:321-8. 1997
    ..Recently, we mapped four members of the family [SCCA1, SCCA2, PAI2, and PI5 (maspin)] to a 300-kb region within 18q21.3. Using a panel of 18q21...
  3. ncbi Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin
    Andrea Varro
    Physiological Laboratory, University of Liverpool, Liverpool, England
    Gastroenterology 123:271-80. 2002
    ..The gastric hormone gastrin regulates acid secretion, gene expression, and the functional development and cellular composition of the gastric mucosa. Using a gene array, we sought to identify major, novel, gastrin-regulated genes...
  4. doi Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2
    Lee Major
    Queensland Institute of Medical Research, Brisbane, PO Royal Brisbane Hospital, Queensland 4029, Australia
    Exp Cell Res 317:338-47. 2011
    Many malignant tissues, including human papilloma virus (HPV)-associated cancers, express SerpinB2, also known as plasminogen activator inhibitor type-2 (PAI-2)...
  5. pmc Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1
    Simon Almeida-Vega
    Physiological Laboratory, School of Biomedical Sciences, University of Liverpool, Liverpool, UK
    Am J Physiol Gastrointest Liver Physiol 296:G414-23. 2009
    ..One putative target is plasminogen activator inhibitor-2 (PAI-2), which is a component of the urokinase activator system that acts extracellularly to inhibit urokinase ..
  6. doi Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, Australia
    Thromb Haemost 104:1133-42. 2010
    ..this proteolytic cascade is exerted by the plasminogen activator inhibitors type-1 (PAI-1/SERPINE1) and 2 (PAI-2/SERPINB2)...
  7. pmc Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli
    Joanna Boncela
    Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland
    J Biol Chem 286:43164-71. 2011
    Quiescent endothelial cells contain low concentrations of plasminogen activator inhibitor type 2 (PAI-2). However, its synthesis can be rapidly stimulated by a variety of inflammatory mediators...
  8. ncbi SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication
    Grant A Darnell
    Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    J Biol Chem 281:31348-58. 2006
    The serine protease inhibitor SerpinB2 (plasminogen activator inhibitor-2) is a major product of activated monocytes and macrophages and is substantially induced during most inflammatory processes...
  9. ncbi Lewis phenotypes and the insulin resistance syndrome in young healthy white men and women
    J O Clausen
    Medical Department C, Glostrup Hospital, Copenhagen, Denmark
    Am J Hypertens 8:1060-6. 1995
    ..029), and plasma glucose (8%, P = .003). The fasting values of serum lipids, plasminogen activator inhibitor (PAI-1) activity, tissue plasminogen activator (t-PA) antigen, and insulin sensitivity did not differ between Le(a-b-) ..
  10. ncbi Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension
    J R Jeng
    Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    Am J Hypertens 11:235-9. 1998
    ..Plasminogen activator inhibitor-1 (PAI-1) was proposed to be a link between the renin-angiotensin system and thrombotic risk...
  11. ncbi Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity. CaptISM Study Group. Captopril Insulin Sensitivity Multicenter Study Group
    D Raccah
    , Marseille, France
    Am J Hypertens 7:731-8. 1994
    ..Lipid parameters, Factor VII (F VII), fibrinogen, plasminogen activator inhibitor 1 (PAI-1), and insulin-like growth factor I (IGF-I) were measured at the same time...
  12. ncbi Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen
    G He
    Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Aarhus University Hospital, Denmark
    Horm Metab Res 32:515-20. 2000
    To investigate further the role of plasminogen activator inhibitor-1 (PAI-1) in human adipose tissue, the regulation of cytokines, cortisol (dexamethasone) as well as estrogen on PAI-1 were determined in human adipose tissue fragments...
  13. ncbi Fibrinolytic function in diuretic-induced volume depletion
    K Lottermoser
    , Bonn, Germany
    Am J Hypertens 13:359-63. 2000
    ..However, 10 days of treatment with HCT significantly increased plasminogen activator inhibitor-1 (PAI-1) antigen (26.8 +/- 5.8 v 21.1 +/- 3.4 ng/mL [p = .037])...
  14. ncbi Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
    Y Erdem
    Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey
    Am J Hypertens 12:1071-6. 1999
    ..We have examined the serum levels of the plasminogen activator inhibitor type-1 (PAI-1) antigen and activity, tissue plasminogen activator (t-PA) antigen and activity, soluble thrombomodulin (sTM), ..
  15. ncbi Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women
    R Fogari
    Department of Internal Medicine and Therapeutics, University of Pavia, Clinica Medica I, IRCCS, Policlinico S. Matteo, Italy
    Am J Hypertens 14:921-6. 2001
    ..of this study was to compare the effects of trandolapril and losartan on plasminogen activator inhibitor type 1 (PAI-1) levels and insulin sensitivity in hypertensive postmenopausal women...
  16. ncbi Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients
    C Rangemark
    Department of Clinical Pharmacology, Sahlgrens and Renströmska Hospital, University of Goteborg, Sweden
    Sleep 18:188-94. 1995
    ..Plasminogen activator inhibitor type 1 (PAI-1) was 18.4 +/- 3.6 IU/ml in OSA patients compared with 8.2 +/- 1.7 IU/ml in controls (p < 0...
  17. ncbi DRL performance in mice with deletion of tPA, uPA or PAI-1 genes
    J M Horwood
    Laboratory of Experimental Psychology, University of Sussex, Falmer, Brighton, BN1 9QG, UK
    Behav Pharmacol 12:487-96. 2001
    ..Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tPA and uPA activity, and is expressed in corresponding brain areas...
  18. ncbi Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes
    H Mallow
    , Genetik und Mikrobiologie, , Germany
    Horm Metab Res 32:500-3. 2000
    ..tumor necrosis factor alpha (TNFalpha), complement factors, adiponectin/adipoQ, plasminogen activator inhibitor-1 (PAI-1), angiotensin II and others...
  19. ncbi [Relation of an increase of von Willebrand factor in the blood, acute myocardial infarction, unstable angina and coronary thrombosis]
    J M Mossard
    Service de cardiologie, , CHU de Strasbourg
    Arch Mal Coeur Vaiss 82:1813-8. 1989
    ..were studied; von Willebrand factor (VWF), fibrinogen, tissue plasminogen activator (t-PA) and its inhibitor (PAI-1) and factor VII...
  20. ncbi Fat cell function and fibrinolysis
    M C Alessi
    Laboratory of Hematology, Faculty of Medicine, CHU Timone, Marseille, France
    Horm Metab Res 32:504-8. 2000
    Plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of plasminogen activators and may be the principal regulator of plasminogen activation in vivo...
  21. pmc Mechanism of angiogenic effects of saponin from ginseng Radix rubra in human umbilical vein endothelial cells
    N Morisaki
    Second Department of Internal Medicine, School of Medicine, Chiba University, Japan
    Br J Pharmacol 115:1188-93. 1995
    ..tPA) as a protease for angiogenesis and the immunoreactivity of its inhibitor, plasminogen activator inhibitor-1 (PAI-1), were measured in conditioned medium of HUVEC stimulated for 24 h with saponin...
  22. ncbi Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria
    S Gasic
    Department of Internal Medicine III, University Hospital of Vienna, Wien, Austria
    Am J Hypertens 12:217-22. 1999
    ..In addition, the effects of ACE-I on plasma levels of plasminogen activator inhibitor (PAI-1) and of tissue plasminogen activator (TPA) were studied...
  23. ncbi Antihypertensive drug treatment and fibrinolytic function
    K Lottermoser
    , , Bonn, Germany
    Am J Hypertens 11:378-84. 1998
    ..activators (tissue-type plasminogen activator [t-PA]) and inhibitors (plasminogen activator inhibitor 1 [PAI-1])...
  24. ncbi Impaired fibrinolysis and insulin resistance in patients with hypertension
    J R Jeng
    Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Republic of China, Taiwan
    Am J Hypertens 9:484-90. 1996
    Plasma plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (tPA) antigens and activities were measured in 28 patients with hypertension and 12 normal controls...
  25. ncbi Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes
    T Skurk
    German Diabetes Research Institute,
    Horm Metab Res 33:196-200. 2001
    ..The major determinant in the fibrinolytic system is the plasminogen activator inhibitor-1 (PAI-1). Both PAI-1 and components of the RAS are over-expressed in the obese state...
  26. ncbi Alterations in the fibrinolytic system components during acute myocardial infarction
    E Ioannidou Papayannaki
    Haematology Laboratory of 2nd Dept of Internal Medicine, Aristotelian University of Thessaloniki, Hippokration Hospital, Greece
    Acta Cardiol 55:247-53. 2000
    ..study was to evaluate the changes in tissue-plasminogen activator (t-PA), plasminogen activator inhibitor - type 1 (PAI-1) and D-dimer (DD) antigen plasma levels in acute myocardial infarction (AMI) patients after thrombolytic therapy ..
  27. ncbi [Diagnosis and treatment of coagulation disorders]
    M M Esnaola Rojas
    , , Buenos Aires, Argentina
    Rev Neurol 29:1290-300. 1999
    ..plasminogen and plasminogen tissue activator (t-PA) and increase in the inhibitor of plasminogen tissue activator (PAI-I); alterations in factors of coagulation such as deficits of factor VII and factor XIII, mutation of prothrombin ..
  28. ncbi Beta-Adrenoceptor agonists and other cAMP elevating agents suppress PAI-1 production of human adipocytes in primary culture
    H Gottschling-Zeller
    , Clinical Department
    Horm Metab Res 32:509-14. 2000
    Recent studies showed that catecholamines contribute to the regulation of plasminogen activator inhibitor-1 (PAI-1) expression, at least in endothelial cells...
  29. ncbi Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women
    I Mertens
    Department of Endocrinology, Metabolism and Clinical Nutrition, University Hospital Antwerp, Faculty of Medicine, University of Antwerp, Belgium
    Horm Metab Res 33:602-7. 2001
    Plasminogen activator inhibitor type 1 (PAI-1), an inhibitor of fibrinolysis and an important and independent cardiovascular risk factor, has been shown to be elevated in obesity and type 2 diabetes...
  30. ncbi Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system
    T Hiraga
    Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan
    Horm Metab Res 28:603-6. 1996
    ..Plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen levels were significantly higher in type IV HL than in the controls...
  31. ncbi A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor
    D J Ballance
    Delta Biotechnology Limited, Nottingham, England
    Eur J Biochem 207:177-83. 1992
    ..growth-factor domain of uPA (amino acids 1-47; GFuPA) at the N-terminus of plasminogen-activator inhibitor type 2 (PAI-2) was produced in Saccharomyces cerevisiae...
  32. ncbi Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract
    K P Radtke
    Forschungslaboratorien der Behringwerke AG, Marburg Lahn
    Biol Chem Hoppe Seyler 371:1119-27. 1990
    Plasminogen activator inhibitor-2 (PAI-2), found in human placenta and pregnancy plasma, was prepared in a highly purified and functionally active form from human placenta...
  33. ncbi Clinical indicators derived from the patient assessment instrument in the long-stay residents of 69 VA nursing homes
    D Rudman
    Department of Medicine, Medical College of Wisconsin, Milwaukee
    J Gen Intern Med 9:261-7. 1994
    ..residents of Veterans Affairs (VA) nursing homes from the standard biannual Patient Assessment Instrument (PAI)...
  34. ncbi Functional activity of eukaryotic signal sequences in Escherichia coli: the ovalbumin family of serine protease inhibitors
    D Belin
    Departement de Pathologie, Universite de Geneve, CH 1211 Geneva, Switzerland
    J Mol Biol 335:437-53. 2004
    ..ovalbumin), cytosolic (leukocyte elastase inhibitor, LEI), or targeted to both compartments (plasminogen activator inhibitor 2, PAI-2)...
  35. ncbi [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion]
    Qing Qing Zhu
    Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
    Zhonghua Jie He He Hu Xi Za Zhi 32:674-8. 2009
    To observe the changes of the concentrations of plasminogen activator inhibitor-1(PAI-1), tissue-type plasminogen activator(t-PA), transforming growth factor-beta(1)(TGF-beta(1)) in peripheral blood and pleural effusion before and after ..
  36. ncbi Interaction and regulation of plasminogen activators and their inhibitor in rat follicles during periovulatory periods
    Y X Liu
    Department of Endocrinology, Institute of Zoology, Academia Sinica, Beijing
    Sci Sin B 31:47-57. 1988
    Ovarian follicles produce two types of plasminogen activator (tPA and uPA), and their inhibitor (PAI)...
  37. ncbi High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma
    Ross Smith
    Department of Surgery, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia
    World J Surg 31:493-502; discussion 503. 2007
    ..that the urokinase-type plasminogen activator (uPA), its receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1), and -2 (PAI-2) play key roles in cancer invasion...
  38. ncbi Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis
    Richard J Fish
    Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital, 24 Rue Micheli du Crest, CH 1205, Geneva, Switzerland
    Exp Cell Res 312:350-61. 2006
    ..We investigated the contribution of serpinB2 (plasminogen activator inhibitor-2, PAI-2) activity in TNF-alpha-induced apoptosis...
  39. ncbi [Atheroma and antithrombotic agents]
    I Juhan-Vague
    , CHU Timone, Marseille
    Arch Mal Coeur Vaiss 85:171-3. 1992
    ..The increases in plasma concentration of factors such as the fibrinogen, factor VII, a fibrinolytic inhibitor, PAI-1, are considered to be markers of coronary risk...
  40. pmc Functional characterization of three adenosine receptor types
    M F Gurden
    Pharmacology Division, Glaxo Group Research, Ware, Hertfordshire
    Br J Pharmacol 109:693-8. 1993
    ..be described by a single rank order of agonist potency: CPA > or = GR79236, R-PIA > or = NECA >> S-PAI > or = metrifudil > or = CV1808, CGS21680. 3...
  41. ncbi Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2
    D N Saunders
    Department of Biological Sciences, University of Wollongong, Northfields Ave, Wollongong 2522, Australia
    J Biol Chem 276:43383-9. 2001
    ..In this study, conformational and functional changes in plasminogen activator inhibitor-2 (PAI-2) following incubation with a panel of synthetic RCL peptides indicated that the P14 residue is critical for RCL ..
  42. pmc Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors
    Richard J Fish
    Department of Internal Medicine, Geneva University Hospital and University Medical Centre, CH 1211 Switzerland
    BMC Mol Biol 5:9. 2004
    ..We have targeted the plasminogen activator inhibitor-2 (PAI-2 or SERPINB2) mRNA using lentiviral vectors for delivery of U6 promoter-driven PAI-2-targeted short hairpin RNA (shRNA) ..
  43. ncbi Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers
    Frances M Stewart
    Reproductive and Maternal Medicine, Division of Developmental Medicine, University of Glasgow, Royal Infirmary Glasgow, United Kingdom
    J Clin Endocrinol Metab 92:969-75. 2007
    ..Obesity in pregnancy is increasing and is a risk factor for metabolic pathology such as preeclampsia. In the nonpregnant, obesity is associated with dyslipidemia, vascular dysfunction, and low-grade chronic inflammation...
  44. ncbi Plasminogen activators and their inhibitors in human saliva and salivary gland tissue
    Oskari J Virtanen
    Department of Virology, Haartman Institute, University of Helsinki, Finland
    Eur J Oral Sci 114:22-6. 2006
    ..The tPA activity in saliva suggests an active proteolysis. Plasminogen activator inhibitor 2 was found to be the main inhibitor of PAs in saliva.
  45. ncbi [Dyslipidemia, lipid lowering drugs and thrombosis]
    P Ambrosi
    Service de cardiologie B, , Marseille
    Arch Mal Coeur Vaiss 88:1641-5. 1995
    ..They are especially marked in hypertriglyceridaemia with raised factor VII, PAI-1 and, sometimes, fibrinogen levels...
  46. ncbi Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin
    S T Olson
    Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Biochemistry 40:11742-56. 2001
    ..and conformational change steps were resolved in the reactions of the serpin, plasminogen activator inhibitor-1 (PAI-1), with tissue plasminogen activator (tPA) and trypsin by comparing the reactions of active and Ser 195-..
  47. ncbi Thrombin inhibits apoptosis of monocytes and plasminogen activator inhibitor 2 (PAI-2) is not responsible for this inhibition
    H Ritchie
    Department of Molecular and Cell Biology, University of Aberdeen, Aberdeen, United Kingdom
    Exp Cell Res 260:20-9. 2000
    b>Plasminogen activator inhibitor 2 (PAI-2) has been shown to inhibit apoptosis in transfected cells. We have investigated this phenomenon in activated human monocytes, which are a physiological source of intracellular PAI-2...
  48. ncbi Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development
    H R Lijnen
    Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
    J Thromb Haemost 5:2259-65. 2007
    ..No information is available, however, on a potential role of plasminogen activator inhibitor-2 (PAI-2) in obesity.
  49. ncbi Expression of dioxin-responsive genes in human endometrial cells in culture
    J h Yang
    School of Medicine, Catholic University of Taegu Hyosung, Taegu, Republic of Korea
    Biochem Biophys Res Commun 257:259-63. 1999
    ..1, 1, 10, or 100 nM TCDD for 24 h. Induction of interleukin-1beta (IL-1beta) and plasminogen activator inhibitor-2 (PAI-2) mRNAs was analyzed by reverse-transcription polymerase chain reaction...
  50. ncbi Topological localization of plasminogen activator inhibitor type 2
    M A Liew
    Department of Biological Sciences, University of Wollongong, Wollongong, NSW, Australia
    Cytometry 40:32-41. 2000
    Plasminogen activator inhibitor type 2 (PAI-2) is a member of the serine protease inhibitor (SERPIN) superfamily and forms stable complexes with urokinase type plasminogen activator (uPA)...
  51. ncbi Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor
    Q Zheng
    Department of General Surgery, Shanghai Sixth Municipal People Hospital, People s Republic of China
    J Cancer Res Clin Oncol 126:641-6. 2000
    ..of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor type-1 (PAI-1) to invasion and metastasis of hepatocellular carcinoma (HCC)...
  52. pmc Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases
    Qingcai Wang
    Department of Medical Oncology, 1441 Eastlake Ave, Norris Building, Room 5334, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    BMC Biochem 4:5. 2003
    The plasminogen activator inhibitor-1 (PAI-1) spontaneously converts from an inhibitory into a latent form...
  53. ncbi Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin
    Alice M Sorrell
    Hannah Research Institute, Ayr KA6 5HL, United Kingdom
    J Biol Chem 281:10883-9. 2006
    ..Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells...
  54. ncbi Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction
    T Soeki
    Department of Cardiology and Clinical Research Institute, Zentsuji National Hospital, Zentsuji City, Kagawa, Japan
    Jpn Circ J 64:547-53. 2000
    Several studies have demonstrated an increased level of plasma plasminogen activator inhibitor-1 (PAI-1) in patients with coronary artery disease (CAD)...
  55. ncbi Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation
    P Lindberg
    Center for Oral Health Sciences, Malmo University, S 214 21 Malmö, Sweden
    Arch Oral Biol 46:23-31. 2001
    ..The PAs are balanced by specific inhibitors (PAI--1 and PAI--2). Local production of t--PA and PAI--2 was recently demonstrated in human gingival tissues...
  56. ncbi The effect of chronic allograft rejection on plasma regulators of fibrinolysis
    A Perkowska
    Transplantation Institute, Warsaw Medical University, Warsaw, Poland
    Ann Transplant 7:44-51. 2002
    ..We evaluated the concentration and activities of tPA, uPA and PAI-I in plasma from kidney allograft recipients...
  57. ncbi [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
    B Hundsdorfer
    Klinik und Poliklinik für Mund Kiefer Gesichts Chirurgie der Technischen Universität München Klinikum rechts der Isar
    Mund Kiefer Gesichtschir 8:180-90. 2004
    ..and prognostic importance of urinase type plasminogen activators (uPA) and of plasminogen activator inhibitors (PAI-1) in cases of primary oral squamous cell carcinoma. Tissue from the primary tumor was taken from 79 patients...
  58. ncbi Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons"
    R J Heine
    Department of Endocrinology, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, The Netherlands
    Horm Metab Res 28:522-6. 1996
    ..seem able to inhibit the fibrinolytic system, possibly via the stimulating effect of proinsulin on the endothelial PAI-1 expression. These observations need further confirmation...
  59. ncbi Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells
    Xiao Yun Hu
    Department of Respiration Medicine, First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, China
    Chin Med J (Engl) 122:2380-5. 2009
    ..effect of CSE on the expression of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in HUVECs was addressed...
  60. ncbi Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice
    H R Lijnen
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Thromb Haemost 74:1126-31. 1995
    ..t-PA) and urokinase-type plasminogen activator (u-PA) (T-U-), of t-PA and plasminogen activator inhibitor-1 (PAI-1) (T-P-), of u-PA and PAI-1 (U-P-) or of t-PA, u-PA, and PAI-1 (T-U-P-) were generated by inbreeding of mice with ..
  61. ncbi Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
    P J Declerck
    Center for Thrombosis and Vascular Research, University of Leuven, Belgium
    J Biol Chem 263:15454-61. 1988
    A binding protein for plasminogen activator inhibitor 1 (PAI-1-BP) was isolated from human plasma by a four-step procedure. 1) The 7 S globulin fraction of plasma was isolated by gel filtration on Sephacryl S-300...
  62. ncbi Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition
    Errol R Norwitz
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 196:382.e1-8. 2007
    ..The balance between plasminogen activator inhibitor-1 (PAI-1) and urokinase (uPA) and tissue-type plasminogen activator (tPA) is an important determinant of proteolytic ..
  63. ncbi Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C
    D De Lucia
    Institute of General Pathology and Oncology, II University of Naples, Italy
    Tumori 83:948-52. 1997
    ..84 volunteers by measuring PT, APTT, fibrinogen, AT III, PC, PS, APC resistance, fibrinolytic system (PLG, ANPL, PAI-1, and t-PA) and activation peptides (D-Dimers, prothrombin 0 fragment 1 + 2/F1 + 2)...
  64. ncbi Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system
    Ruth Miskin
    Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel
    J Mol Cell Cardiol 38:715-22. 2005
    Plasminogen activator inhibitor-1 (PAI-1) is a major physiological regulator of the fibrinolytic system and is thought to promote vascular diseases...
  65. ncbi Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice
    T Kawasaki
    Center for Molecular and Vascular Biology, University of Leuven, and Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Blood 96:153-60. 2000
    The role of plasminogen activator inhibitor-1 (PAI-1) in the plasma, blood platelets, and vessel wall during acute arterial thrombus formation was investigated in gene-deficient mice...
  66. ncbi Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients
    R Ando
    Department of Internal Medicine, Nakano General Hospital, Tokyo, Japan
    Clin Nephrol 58:25-32. 2002
    ..We investigated the association of DNA polymorphisms for beta-fibrinogen, factor VII, and PAI-1 with plasma levels of these factors and with ischemic heart disease (IHD) and cerebral infarction (CI) in ..
  67. ncbi Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome
    Charles J Glueck
    Cholesterol Center, Jewish Hospital, MDL Laboratories, Cincinnati, OH 45229, USA
    Metabolism 55:345-52. 2006
    We assessed whether hypofibrinolytic plasminogen activator inhibitor 1 (PAI-1 activity) showed an independent association with first-trimester miscarriage in the 430 women with polycystic ovary syndrome (PCOS) who had previous ..
  68. ncbi Expression of the plasminogen activator system in the human vascular wall
    M Y Salame
    Department of Cardiology, Glenfield General Hospital, England, Leicester, UK
    Atherosclerosis 152:19-28. 2000
    ..tissue plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and the uPA receptor (uPAR), in normal and atheromatous human vascular tissue obtained at coronary and ..
  69. ncbi Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
    G Konecny
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1678, USA
    Clin Cancer Res 7:2448-57. 2001
    ..enzyme, urokinase-type plasminogen activator (uPA), or its inhibitor, plasminogen activator inhibitor-1 (PAI-1), in colon and gastric cancer...
  70. ncbi Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study
    Gordana Horvatić Herceg
    Clinical Department of Nuclear Medicine and Radiation Protection, Clinical Hospital Centre Zagreb, Zagreb, Croatia
    Wien Klin Wochenschr 118:601-9. 2006
    Higher levels of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) are linked to the poor prognosis in a variety of malignances...
  71. doi Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients
    Youming Peng
    Division of Nephrology, Nephrology Institute of Central South University, Changasha, Hunan, China
    Nephrology (Carlton) 13:579-86. 2008
    The aim of the present report was to investigate the probable association of circulating levels of PAI-1 and expression of PAI-1 in internal iliac artery walls with atherosclerotic disease in chronic haemodialysis (HD) patients.
  72. ncbi Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity
    J Boncela
    Center for Microbiology and Virology, Polish Academy of Sciences 93 232 Lodz, Poland
    J Biol Chem 276:35305-11. 2001
    ..one of the major acute phase proteins, was found to interact with plasminogen activator inhibitor type 1 (PAI-1) and to stabilize its inhibitory activity toward plasminogen activators...
  73. ncbi Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells
    S B Jakowlew
    National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850, USA
    Growth Factors 14:177-97. 1997
    ..1 and PMA both caused a persistent increase in expression of the mRNAs for both plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator (PA) up to 24 hr in most NSCLC cells, with the increase in PAI-1 mRNA beginning ..
  74. ncbi Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)
    W U Atiomo
    Departments of Gynaecology, Haematology and Endocrinology, Derriford Hospital, Plymouth, UK
    Clin Endocrinol (Oxf) 52:487-92. 2000
    It has been postulated that an insulin-driven increase in plasminogen activator inhibitor-1 (PAI-1) levels may link insulin resistance to anovulatory infertility in women with PCOS and that it may place them at increased risk of ..
  75. ncbi Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies
    C Floridon
    Department of Pathology, Odense University Hospital, Denmark
    Placenta 21:754-62. 2000
    Urokinase plasminogen activator, its receptor and the inhibitor PAI-1 are believed to control proteolysis and remodelling of maternal tissue during trophoblast invasion...
  76. pmc Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization
    S M Nordstrom
    Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
    Bone 41:995-1004. 2007
    The plasminogen activation system (PAS) and its principal inhibitor, plasminogen activator inhibitor-1 (PAI-1), are recognized modulators of matrix...
  77. ncbi Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent
    Jacqueline M Cale
    Department of Internal Medicine, Cardiovascular Research Center, University of Michigan, 1150 W Medical Center Dr, Ann Arbor, MI 48109, USA
    Curr Drug Targets 8:971-81. 2007
    Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively)...
  78. ncbi On the regulation of the plasminogen activator inhibitor-1 gene expression
    K Descheemaeker
    Centre for Thrombosis and Vascular Research K U, Leuven
    Verh K Acad Geneeskd Belg 55:225-64. 1993
    ..The main physiological inhibitor of the plasminogen activators is plasminogen activator inhibitor-1 (PAI-1)...
  79. ncbi Prolactin regulation of tissue type plasminogen activator and plasminogen activator inhibitor type-I gene expression in eCG-primed rat granulosa cells in culture
    Y X Liu
    State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100080, China
    Biol Reprod 59:409-16. 1998
    The present study was designed to investigate the effect of prolactin (PRL) on plasminogen activator inhibitor-I (PAI-I) and tissue type plasminogen activator (tPA) gene expression in eCG-primed granulosa cells in vitro...
  80. ncbi The expression of plasminogen activator system in a rat model of periodontal wound healing
    Y Xiao
    School of Dentistry, The University of Queensland, Brisbane, Australia
    J Periodontol 72:849-57. 2001
    ..The aim of this study was to elucidate the presence of components of the plasminogen activator system during different stages of periodontal wound healing...
  81. ncbi Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1
    A R Rezaie
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Biochemistry 37:13138-42. 1998
    Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor of the serpin superfamily which rapidly inactivates tissue plasminogen activator (tPA), but reacts with thrombin at a much slower rate...
  82. ncbi Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
    Y Zhu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Circulation 99:3050-5. 1999
    ..Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tPA, may contribute to arterial thrombolysis resistance...
  83. ncbi Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer
    S B Fox
    Anatomical Pathology, Canterbury Health Labs, Christchurch Hospital, Christchurch, New Zealand
    J Pathol 195:236-43. 2001
    ..tumour types, elevated levels of uPA, its receptor (uPAR) or its inhibitor plasminogen activator inhibitor-1 (PAI-1) is associated with a poorer prognosis...
  84. ncbi Plasminogen activator inhibitor-1 mRNA expression in cultured pigmented ciliary epithelial cells of the porcine eye
    Michael W Meyer
    Department of Ophthalmology, Medical School Hanover, Carl Neuberg Strasse 1, 30625 Hanover, Germany
    Graefes Arch Clin Exp Ophthalmol 240:679-86. 2002
    Plasminogen activator inhibitor-1 (PAI-1) is a main regulator of the fibrinolytic system...
  85. ncbi [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
    En min Zhao
    Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
    Zhonghua Er Bi Yan Hou Ke Za Zhi 38:39-42. 2003
    ..the expression of urokinase-type plasminogen activator (uPA) and its inhibitors(plasminogen activator inhibitors, PAI) type-1 and type-2 in squamous cell carcinoma of human larynx and reveal the correlation of the major ..
  86. ncbi Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases
    Andrey A Komissarov
    Division of Biochemical Research, Department of Pathology, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Biol Chem 280:1482-9. 2005
    The serpin plasminogen activator inhibitor-1 (PAI-1) is a potential therapeutic target in cardiovascular and cancerous diseases. PAI-1 circulates in blood as a complex with vitronectin...
  87. ncbi Adrenal failure due to metastasis both to the hypothalamic-pituitary area and the adrenals
    P Trincado
    Department of Endocrinology, Hospital Miguel Servet, Zaragoza, Spain
    Tumori 82:401-4. 1996
    ..three months, and progressively, he developed anterior pituitary failure, as well as primary adrenal insufficiency (PAI) due to metastasis in both adrenals...
  88. ncbi Percutaneous alcohol injection of portal thrombosis in hepatocellular carcinoma: a new possible treatment
    T Livraghi
    Servizio di Radiologia, Ospedale Civile, Vimercate, Milano, Italy
    Tumori 76:394-7. 1990
    ..portal thrombosis is usually regarded as a contraindication for surgery and for percutaneous alcohol injection (PAI). For palliative purposes we used PAI in 4 patients with infiltrative HCC and segmental portal thrombosis...
  89. ncbi Can axillary dissection be avoided by improved molecular biological diagnosis?
    T Lindahl
    Department of Oncology, Akademiska sjukhuset, Uppsala University, Sweden
    Acta Oncol 39:319-26. 2000
    ..g. c-erbB-2, p53, uPA, PAI-I and VEGF...
  90. ncbi The factor structure of the Personality Assessment Inventory-Borderline Features (PAI-BOR) Scale in a nonclinical sample
    K M Jackson
    University of Missouri-Columbia, MO 65211, USA
    J Pers Disord 15:536-45. 2001
    ..fit of Morey's (1991) proposed 4-factor structure on Personality Assessment Inventory-Borderline Features Scale (PAI-BOR; Morey, 1991) items in a sample of approximately 5,000 nonclinical participants...
  91. ncbi Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis
    M M al-Mugeiren
    Department of Paediatrics, King Khalid University Hospital, Riyadh, Saudi Arabia
    Haemostasis 26:304-10. 1996
    ..C and S] and the fibrinolytic factors, tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI). The study groups consisted of 41 children (ages ranging from 2 to 14 years; median 7...
  92. ncbi Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
    P Eriksson
    King Gustaf V Research Institute, Department of Medicine, Karolinska Hospital, Stockholm, Sweden
    Arterioscler Thromb Vasc Biol 18:20-6. 1998
    ..lipoproteins may attenuate fibrinolysis by increasing the plasma levels of plasminogen activator inhibitor-1 (PAI-1)...
  93. ncbi Update on plasminogen activator inhibitor-1
    D Vaughan
    Cardiology Division, Vanderbilt University, Nashville, TN 37232, USA
    Can J Cardiol 14:14D-15D. 1998
    Plasminogen activator inhibitor-1 (PAI-1) is produced by the endothelium and determines the rate and extent of fibrinolysis...
  94. ncbi Plasminogen activator inhibitor-1 is expressed in cultured rat Sertoli cells
    B Le Magueresse-Battistoni
    INSERM U407, Centre Hospitalier Lyon Sud, 69495 Pierre Benite Cedex, France
    Biol Reprod 59:591-8. 1998
    ..compartments of the seminiferous tubules, whereas peritubular cells secrete plasminogen activator inhibitor-1 (PAI-1), a fast-acting and specific PA inhibitor...
  95. ncbi ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes
    S De Cosmo
    Division and Research Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy
    Diabetes Metab Res Rev 15:247-53. 1999
    ..angiotensin converting enzyme (ACE): insertion/deletion (I/D) polymorphism, plasminogen activator inhibitor-1 (PAI-1): 4G/5G polymorphism, decorin: 179/183/185 polymorphism and Werner syndrome helicase: C/R polymorphism, with the ..
  96. ncbi Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression
    M Sandstrom
    Department of Oncology, Umea University, Sweden
    Int J Dev Neurosci 17:473-81. 1999
    ..This model could be of value when evaluating different treatment modalities aimed at blocking the migrating capacity and growth of glial tumors...
  97. ncbi New approaches for genotyping of Helicobacter pylori based on amplification of polymorphisms in intergenic DNA regions and at the insertion site of the cag pathogenicity island
    S Bereswill
    Institute of Medical Microbiology and Hygiene, Department of Microbiology, University Hospital Freiburg, Germany
    Med Microbiol Immunol 189:105-13. 2000
    ..of single genes as well as of a large virulence-associated genomic DNA region, the cag pathogenicity island (PAI)...
  98. ncbi Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen
    N J Brown
    Divisions of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Arterioscler Thromb Vasc Biol 21:1071-7. 2001
    Activation of the renin-angiotensin-aldosterone system (RAAS) is associated with increased circulating PAI-1 antigen and increased risk of thrombotic cardiovascular events...
  99. ncbi Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells
    T K Nordt
    Department of Cardiology, University of Freiburg, Germany
    Thromb Haemost 86:1305-13. 2001
    Human atherosclerotic lesions exhibit increased expression of plasminogen activator inhibitor type-1 (PAI-1) that has been implicated in atherogenesis...
  100. ncbi Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project
    G Y H Lip
    Haemostasis Thrombosis Unit, University Department of Medicine, City Hospital, Birmingham, UK
    Blood Coagul Fibrinolysis 13:339-47. 2002
    ..factor (vWf)], platelet activation (soluble P-selectin) and thrombogenesis [plasminogen activator inhibitor (PAI), and fibrin D-dimer] are common in cardiovascular disease...
  101. ncbi Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects
    Nicola Pannacciulli
    Internal Medicine, Endocrinology, and Metabolic Diseases, Department of Emergency and Transplant, University of Bari, Bari, Italy
    Obes Res 10:717-25. 2002
    The aim of our study was to examine whether plasminogen activator inhibitor-1 (PAI-1) plasma levels varied as a function of differences in glucose tolerance status independently of body fatness, body-fat distribution, and insulin ..

Research Grants68

  1. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
    ..The major inhibitor of Pg activation, Plasminogen Activator Inhibitor-1 (PAI-1), regulates this process at the level of the primary physiological activators, urokinase-type plasminogen ..
  2. William P Fay; Fiscal Year: 2016
    ..Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor and a major regulator of fibrinolysis and cell migration...
  3. RICHARD LOUIS KLEIN; Fiscal Year: 2015
    ..contains higher concentrations of S1P than HDL2, both stimulate the release of plasminogen activator inhibitor-1 (PAI-1) from adipocytes and, importantly, that circulating S1P concentrations are significantly increased in patients ..
  4. Urokinase, Neutrophil Activation and Acute Lung Injury.
    Gang Liu; Fiscal Year: 2013
    ..with increases in circulating and pulmonary concentrations of urokinase (uPA), plasminogen activator inhibitor 1 (PAI-1), and vitronectin, are present in almost all patients with acute lung injury (ALI)...
  5. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
    ..has been identified as playing a role in both inflammation and thrombosis is plasminogen activator inhibitor-1 (PAI-1), and very recent data suggests that PAI-1 may also play a role in regulating lipid metabolism...
  6. DOUGLAS EUGENE VAUGHAN; Fiscal Year: 2016
    ..for this association, we have focused on the interaction between the RAAS and plasminogen activator inhibitor-1 (PAI-1)...
  7. Zhongwu Liu; Fiscal Year: 2014
    ..activity of tissue plasminogen activator (tPA) via modifying the balance of tPA/plasminogen activator inhibitor-1(PAI-1) level...
  8. REGULATION OF VASCULAR FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 2003
    Plasminogen activator inhibitor 1 (PAI-1) is the primary inhibitor of plasminogen activation and vascular fibrinolysis in vivo, and elevations in PAI-1 appear to compromise normal fibrin clearance mechanisms and promote pathological ..
  9. MOLECULAR INTERACTIONS OF FIBRINOLYSIS
    John Anagli; Fiscal Year: 2005
    ..on a molecular level, the mechanisms of inhibitory control of fibrinolysis by plasminogen activator inhibitor-1 (PAI-1)...
  10. Regulation of Pal-1 in Atherosclerosis and Thrombosis
    Yolanda M Fortenberry; Fiscal Year: 2013
    ..and hypertension. Elevated plasma levels of the serine protease inhibitor, plasminogen activatoMnhibitor-1, (PAI- 1) are correlated with these'risk factors and:several other thrombotic disorders..PAI-1.is the-...
  11. Maria Mori Brooks; Fiscal Year: 2014
    ..During the five- year follow-up, plasminogen activator inhibitor-1 (PAI-1), C-reactive protein (CRP), fibrinogen, and D-dimer were lower in the insulin sensitization group compared with ..
  12. ANGARA KONETI RAO; Fiscal Year: 2016
    ..VIIa, and VIII~ plasma TAT~ D-dimer~ tissue factor pathway inhibitor (TFPI)~ and plasminogen activator inhibitor-1 (PAI-1)] will be measured before and at 48 hours after the start of treatment...
  13. Karen Block; Fiscal Year: 2015
    ..protein degradation by inducing inhibitors of matrix-degrading enzymes such as plasminogen activator inhibitor-1 (PAI-I)...
  14. Punam Malik; Fiscal Year: 2016
    ..expression of the potent pulmonary vasoconstrictor ET-1, and a procoagulant, plasminogen activator inhibitor-1 (PAI-1), from human pulmonary microvascular endothelial cells (HPMVEC)...
  15. Dichotomous Roles of Thrombin in Acetaminophen Hepatotoxicity
    ROBERT ANDREW ROTH; Fiscal Year: 2013
    ..The deposition of fibrin is enhanced by the antifibrinolytic activity of plasminogen activator inhibitor-1 (PAI-1), a plasma protein the expression of which is induced by the transcription factor, hypoxia inducible factor-..
  16. Yves A DeClerck; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Plasminogen activator inhibitor-1 (PAI-1) is a member of the family of endogenous serine protease inhibitors (serpins) that controls the activation of plasminogen into plasmin by tissue and urokinase ..
  17. PAI-1 and Vitronectin in Failure of Coronary Revascularization
    William P Fay; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue- and urinary-type plasminogen activators...
  18. Regulation of Transcriptional Activity of Hypoxia Inducible Factor 2
    Cheng Jun Hu; Fiscal Year: 2012
    ..Finally, we showed that USF2 and HIF2( activated PAI-1 promoter synergistically while USF2 dominant-negative inhibited HIF2(-mediated PAI-1 promoter activation...
  19. Ah Receptor Anatomy: Implications for Dioxin Toxicity
    CORNELIS JOHAN ELFERINK; Fiscal Year: 2011
    ..and relative contribution of cyclin-dependent kinase 2 (CDK2) inhibi- ion and plasminogen activator inhibitor-1 (PAI-1) expression on liver regeneration...
  20. Pathogenesis of Lymphangioleiomyomatosis
    Lucia Schuger; Fiscal Year: 2010
    ..corresponding inhibitors, tissue inhibitor of metalloproteinases-3 (TIMP-3) and plasminogen activator inhibitor-1 (PAI-1) are downregulated, resulting in an enzymatic imbalance that favors ECM degradation...
  21. Yi Ping Shih; Fiscal Year: 2016
    ..also discovered that loss of DLC1 enhances angiogenesis by upregulating VEGF and plasminogen activator inhibitor 1 (PAI-1) expression...
  22. Ah receptor transcriptional regulation through a novel DNA binding site
    SHELLY RENEE WILSON; Fiscal Year: 2012
    ..Preliminary evidence examining TCDD induction of plasminogen activator inhibitor-1 (PAI-1), a key protein in liver regeneration, exposed a novel AhR-dependent regulatory mechanism involving DNA binding ..
  23. BMP Regulation of TGF-b2 in the Trabecular Meshwork
    Robert J Wordinger; Fiscal Year: 2012
    ..indicates that (a) BMP-4 inhibits TGF-22 stimulation of fibronectin (FN) and plasminogen activator inhibitor-1 (PAI-1) secretion by cultured TM cells and (b) gremlin, a BMP antagonist is upregulated in multiple glaucomatous TM cell ..
  24. Exercise Effects on Serum Biomarkers of Angiogenesis
    CATHERINE ROSE DUGGAN; Fiscal Year: 2012
    ..growth factor (VEGF), osteopontin, pigment epithelium-derived factor (PEDF) and plasminogen activator inhibitor-1(PAI-1)...
  25. Role of plasminogen activator inhibitor-1 in mediating age-related fibrosis
    David Lu; Fiscal Year: 2013
    ..While numerous studies have correlated increases in plasminogen activator inhibitor-1 (PAI-1) with aging, none have directly examined possible mechanisms of PAI-1-mediated inhibition of collagen turnover...
  26. Anne S Henkel; Fiscal Year: 2016
    ..patients with NASH have increased circulating levels and hepatic expression of plasminogen activator inhibitor-1 (PAI-1), however it is unknown whether this association is causative or simply correlative...
  27. The role of Plasminogen activator Inhibitor-1 in Helicobacter pylori infection.
    Sarah E Keates; Fiscal Year: 2010
    ..with the bacterial pathogen Helicobacter pylori causes an upregulation of Plasminogen activator inhibitor-1 (PAI-1), which contributes to gastric cancer progression. Aim 1 examines how H...
  28. Regulation of Host Response in S. pneumoniae Infections
    Jian dong Li; Fiscal Year: 2010
    ..Of particular clinical significance is the direct evidence for the efficacy of the exogenous administration of PAI-1 in reducing alveolar hemorrhage and early lethality without serious adverse effects...
  29. CONTROL OF DRUG AND ETHANOL METABOLISM
    Gavin E Arteel; Fiscal Year: 2010
    ..Specifically, we showed that hepatic expression of plasminogen activator inhibitor-1 (PAI-1) is upregulated by ethanol and the level of expression correlates with protection against liver damage in enteral ..
  30. Agnes B Fogo; Fiscal Year: 2016
    ..we have shown that high doses of angiotensin inhibition, linked to decreased plasminogen activator inhibitor-1 (PAI-1), could regress existing glomerulosclerosis over the short term...
  31. Mechanism of PAI-1 Polarization to Myoendothelial Junctions
    Brant E Isakson; Fiscal Year: 2013
    ..During the course of metabolic syndrome, there is a significant increase in plasminogen activator inhibitor-1 (PAI-1);however the pathological role that PAI-1 plays during the course of the disease is not clear...
  32. DANIELLE S BENOIT; Fiscal Year: 2016
    ..fibrosis in a variety of pathologies is associated with TGF-21 induction of plasminogen activator inhibitor-1 (PAI-1) that prevents activation of MMPs, TGF-23 has anti-scarring effects in cutaneous wound healing...
  33. PAI-1 Targeted Intrapleural Fibronolytic Therapy
    Andrey Komissarov; Fiscal Year: 2012
    ..These are important clinical problems that mandate the search for better IPFT. Plasminogen activator inhibitor-1 (PAI-1) is strongly implicated in the pathogenesis of pleural loculation and inhibits tissue and urokinase plasminogen ..
  34. REGULATION OF ANGIOGENESIS BY PAI1
    Daniel Lawrence; Fiscal Year: 2001
    ..of the anti-angiogenic effect observed in our preliminary studies with plasminogen activator inhibitor-1 (PAI-1)...
  35. GENETIC ARCHITECTURE OF PLASMA T-PA AND PAI-1
    Jason Moore; Fiscal Year: 2004
    ..In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (T-PA), NAD T-PA/PA-1 complexes have been found to correlate with increased ..
  36. GENETIC VARIANTS AND THROMBOSIS
    Patricia Hebert; Fiscal Year: 2004
    ..In particular, elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), and t-PA/PAI-1 complexes have been found to correlate with increased ..
  37. PLASMINOGEN ACTIVATOR INHIBITOR-1 IN ATHEROSCLEROSIS
    DANIEL EITZMAN; Fiscal Year: 2001
    ..RESEARCH PROPOSAL: The goal of this grant is to define the role of type I plasminogen activator inhibitor (PAI-1) in the development of intimal lesion formation during atherogenesis and following vascular injury...
  38. Mechanisms of Hemostatic Protease Inhibition by Serpins
    Ingrid M Verhamme; Fiscal Year: 2010
    ..of thrombin (T) inhibition by the serpins, heparin cofactor II (HCII) and plasminogen activator inhibitor-1 (PAI-1), implicated in arterial thrombosis...
  39. MECHANISMS UNDERLYING CARDIOVASCULAR RISKS IN DIABETES
    Gordon Williams; Fiscal Year: 2000
    ..and hyperglycemia in combination with differences in the specific alleles of the genes of the renin-angiotensin and PAI-1 systems that predispose the individual to vascular complications...
  40. MECHANISMS OF CARDIOVASCULAR DISEASE IN OBESITY
    David Loskutoff; Fiscal Year: 2002
    ..Although plasminogen activator inhibitor 1 (PAI-1) is consistently and significantly elevated in the plasma of obese humans and is a known risk factor for ..
  41. VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENES
    Gordon Williams; Fiscal Year: 2001
    ..to address three of these: 1) the renin-angiotensin system (RAS), 2) the plasminogen- activator-inhibitor-1 (PAI-1) system, and 3) the metabolic abnormalities associated with insulin resistance...
  42. AGE RELATED CONFORMATIONAL MODIFICATIONS OF PROTEIN
    Ari Gafni; Fiscal Year: 2003
    ..enzyme phosphoglycerate kinase (PGK) and the fibrinolysis-associated protein plasminogen activator inhibitor-1 (PAI-1)...
  43. Regulation of angiotensin-induced PAI-1 expression
    EDWARD FEENER; Fiscal Year: 2006
    ..and from other groups, have demonstrated that AngII is a potent stimulator of plasminogen activator inhibitor-1(PAI-1) expression in cultured vascular cells and RAS inhibition reduces neointimal PAI-1 expression in vascular tissues ..
  44. Cardiac Risk:Insulin Resistance, Hypertension, & PAI-1
    Abraham Thomas; Fiscal Year: 2006
    ..Plasminogen activator inhibitor-1 (PAI-1) is an important peptide in the fibrinolytic-thrombotic pathway and elevated levels of PAI-1 have been shown to ..
  45. PPARGAMMA AND AII IN GLOMERULOSCLEROSIS
    Willa Hsueh; Fiscal Year: 2002
    ..Plasminogen activator inhibitor-1 (PAI-1) is produced by mesangial cells in response to growth factor stimulation, is increased in glomeruli of diabetic ..
  46. TLR2 in Sepsis-Induced Coagulopathy, Endothelial Leak, and Pulmonary Dysfunction
    Judith Hellman; Fiscal Year: 2010
    ..of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and plasminogen activator inhibitor type 1 (PAI-1) will be quantified...
  47. Deranged Coagulation and Fibrinolytic Cascades in Idiopathic Pulmonary Fibrosis
    MITCHELL ALAN OLMAN; Fiscal Year: 2013
    ..there is activation of coagulation (increased tissue factor antigen), and inhibition of fibrinolysis (increased PAI-1 antigen) in plasma from patients with IPF...
  48. Zheng Gang Zhang; Fiscal Year: 2016
    ..and astrocytes, which leads to reduction of thrombosis by downregulation of plasminogen activator inhibitor1 (PAI-1)...
  49. ENDOTHELIAL CELL PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2
    Raymond Schleef; Fiscal Year: 1990
    ..that cultured ECs also produce two immunological distinct plasminogen activator inhibitors, including both type 1 (PAI-1) and type 2 (PAL-2), introduces a previously unsuspected level of complexity to our understanding of this system, ..
  50. HUMAN PLASMINOGEN ACTIVATOR-INHIBITOR PAI-1 GENE
    David Ginsburg; Fiscal Year: 1991
    ..plasminogen activator (tPA) and its specific, rapidly acting inhibitor, plasminogen activator inhibitor (PAI-1)...
  51. Michael Chopp; Fiscal Year: 2015
    ..in astrocytes, neurons and endothelial cells via the Shh signaling pathway;b) MSCs down-regulate TGF-[unreadable]1/PAI-1 via the Shh signaling pathway and thereby increase tPA activity...
  52. Thrombolysis in Pediatric Stroke Study (TIPS)
    Catherine M Amlie-Lefond; Fiscal Year: 2013
    ..The two secondary aims are: (1) To measure the pharmacokinetics of tPA, including free tPA, PAI-1, and tPA antigen in children receiving IV tPA for acute AIS...
  53. PLASMINOGEN ACTIVATORS AND PA INHIBITORS IN MALIGNANCY
    Robert Cohen; Fiscal Year: 1993
    ..of urokinase (UK) and tissue plasminogen activator (t-PA), potential modulating influences of the PA inhibitors PAI-1 and PAI-2 on the malignant phenotype will be investigated...
  54. Toni M Antalis; Fiscal Year: 2016
    ..Objectives: Using clinically relevant experimental models of DVT, we discovered that genetic deletion of PAI- 2 in mice accelerates venous thrombus resolution...
  55. Coagulation Abnormalities and Post-Traumatic Ventilator-Associated Pneumonia
    Jean Francois Pittet; Fiscal Year: 2013
    ..with (a) low plasma levels of aPC and (b) an inhibition of the fibrinolysis caused by elevated plasma levels of PAI-1...
  56. ENDOTHELIAL CELL MEDIATED FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 1991
    ..endothelial cells (BAEs) produce not one, but multiple plasminogen activators (PAs) as well as a PA inhibitor (PAI) that can modulate their activities...
  57. R Graham Barr; Fiscal Year: 2016
    ..2) Endothelium-dependent hypercoagulation, measured by PAI-1, and plasma viscosity is associated with greater TPVV, lower LV end-diastolic volume, greater emphysema and ..
  58. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ..CRP) and anti-inflammatory (adiponectin isoforms) adipocytokines and parameters of impaired coagulant balance (PAI-1, fibrinogen, D-dimer, TAFI) in 50% of patients enrolled in the Look AHEAD trial and how this relationship is ..
  59. Role of Matrix Metalloproteinase-1 in Endothelial Cell Senescence
    Catherine D Mao; Fiscal Year: 2010
    ..in the control of lifespan and cell senescence and by the up-regulation of plasminogen activator inhibitor (PAI)-1 and matrix metalloproteinase (MMP)-1, two secreted markers of cell senescence and age-related diseases...
  60. STRONG HEART FAMILY STUDY
    Shelley A Cole; Fiscal Year: 2011
    ..5) and lean body mass (LOD=2.6) (chr 2p);ejection fraction (chr 1q, LOD=3.5);LDL-C (chr 10p, LOD=3.7);PAI-1 (chr 11p,LOD=3...
  61. CONTROL OF FIBRIN TURNOVER IN PLEURAL DISEASE
    Steven Idell; Fiscal Year: 2004
    ..Derangements of the regulation of plasminogen activator inhibitor -1 (PAI-1) and the urokinase receptor (uPAR) by pleural mesothelial cells appear to be critical determinants of locally ..
  62. Occult Small Vessel Cerebrovascular Disease in High Risk Families
    PAUL ALAN NYQUIST; Fiscal Year: 2013
    ..inflammatory (IL-6, TNF-[unreadable], hs- CRP, sVCAM-1, sICAM1, and MCP-1) and prothrombotic factors (PAI-1, Lp(a) and fibrinogen), endothelium dependent vascular reactivity (flow mediated dilatation [FMD] of the brachial ..
  63. VASOACTIVE HORMONE INDUCED GENES IN DIABETIC VASCULATURE
    EDWARD FEENER; Fiscal Year: 1999
    ..display, I have discovered that angiotensin II (AII) is a potent stimulator of plasminogen activator inhibitor-2 (PAI-2) expression in rat microvessel endothelial (RME) cells and rat aortic smooth muscle cells (RASMC)...
  64. MATRIX MEDIATORS OF WOUND HEALING
    Paul J Higgins; Fiscal Year: 2010
    Plasminogen activator inhibitor type-1 (PAI-1) is the major physiologic regulator of the plasmin-based pericellular proteolytic cascade and a critical element in pathologic angiogenesis in vivo. PAI-1 controls stromal proteolysis (i.e...
  65. MACROPHAGE/NEUTROPHIL ELASTASE INHIBITOR
    EILEEN REMOLD O DONNELL; Fiscal Year: 1999
    ..will be examined in macrophages in comparison with regulation of expression of plasminogen activator inhibitor-2 (PAI-2), a closely related molecule...
  66. A THECAL ROLE IN OVULATION
    KATHERINE ROBY; Fiscal Year: 1999
    ..and requisite for the process of ovulation are the plasminogen activator (PA) and plasminogen activator inhibitor (PAI) genes. In response to LH, PAI is decreased and PA increases...
  67. Helicobacter pylori and the gastric microbial community in rhesus macaques
    Jay V Solnick; Fiscal Year: 2010
    ..factor associated with development of gastric cancer and peptic ulcer is the cag pathogenicity island (cag PAI). We recently used the rhesus macaque model to demonstrate that H...

Patents2

  1. VARIANTS OF PAI-2
    Patent Number: WO9109124-A1; Date:1991-06-27
  2. POLYPEPTIDE PRODUCTION IN FUNGI
    Patent Number: WO9102057-A1; Date:1991-02-21